Carisma Therapeutics Grants Executive Stock Options for Retention

Carisma Therapeutics (CARM) has shared an announcement.

Carisma Therapeutics Inc. has issued special stock options to key executives as a retention and incentive strategy. President and CEO Steven Kelly, CFO Richard Morris, and Chief Scientific Officer Michael Klichinsky have been granted options for 125,000, 85,000, and 85,000 shares respectively, aligning their interests with the company’s growth and rewarding their contributions. These options will vest over two years, ensuring continued leadership stability. Additional grants for other employees are also planned, reinforcing Carisma’s commitment to maintaining a motivated workforce.

See more data about CARM stock on TipRanks’ Stock Analysis page.